Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-09 5:09 pm Sale | 13G | VINCERX PHARMA, INC VINC | GOLDMAN SACHS GROUP INC GS | 631,490 3% | -1,078,166 (-63.06%) | View |
| 2024-02-14 5:10 pm Sale | 13G | VINCERX PHARMA, INC VINC | Long Focus Capital Management LLC | 1,098,753 5.1% | -316,198 (-22.35%) | View |
| 2024-02-13 7:05 pm Purchase | 13G | VINCERX PHARMA, INC VINC | BANK OF AMERICA CORP BAC | 1,082,863 5.1% | 1,082,863 (New Position) | View |
| 2024-02-13 4:55 pm Sale | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 0 0% | -1,492,771 (Position Closed) | View |
| 2024-02-05 5:35 pm Sale | 13G | VINCERX PHARMA, INC VINC | GOLDMAN SACHS GROUP INC GS | 1,709,656 8% | -438,193 (-20.40%) | View |
| 2023-02-14 4:03 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Long Focus Capital Management LLC | 1,414,951 6.7% | 1,414,951 (New Position) | View |
| 2023-02-13 4:11 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,492,771 7.04% | 357,406 (+31.48%) | View |
| 2023-02-10 4:00 pm Sale | 13G | VINCERX PHARMA, INC VINC | Rubric Capital Management LP | 386,719 1.83% | -1,720,281 (-81.65%) | View |
| 2023-02-10 1:46 pm Purchase | 13G | VINCERX PHARMA, INC VINC | GOLDMAN SACHS GROUP INC GS | 2,147,849 10.1% | 70,975 (+3.42%) | View |
| 2023-02-08 09:53 am Purchase | 13G | VINCERX PHARMA, INC VINC | GOLDMAN SACHS GROUP INC GS | 2,076,874 9.8% | 2,076,874 (New Position) | View |
| 2022-12-29 5:25 pm Sale | 13G | VINCERX PHARMA, INC VINC | Flynn James E | 0 0% | -1,379,310 (Position Closed) | View |
| 2022-02-14 4:00 pm Purchase | 13G | VINCERX PHARMA, INC VINC | TANG CAPITAL PARTNERS LP | 1,030,634 4.9% | 1,030,634 (New Position) | View |
| 2022-02-14 11:22 am Unchanged | 13G | VINCERX PHARMA, INC VINC | PUTNAM INVESTMENTS LLC | 0 0% | 0 (Unchanged) | View |
| 2022-02-14 09:32 am Sale | 13G | VINCERX PHARMA, INC VINC | RTW INVESTMENTS LP | 741,236 3.5% | -8,764 (-1.17%) | View |
| 2022-02-11 4:13 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,135,365 5.39% | 59,145 (+5.50%) | View |
| 2022-02-10 12:41 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Rubric Capital Management LP | 2,107,000 10.006% | 2,107,000 (New Position) | View |
| 2021-11-22 2:50 pm Purchase | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors LLC | 1,076,220 5.12% | 1,076,220 (New Position) | View |
| 2021-09-28 11:29 am Purchase | 13G | VINCERX PHARMA, INC VINC | Flynn James E | 1,379,310 6.56% | 1,379,310 (New Position) | View |
| 2021-08-04 2:23 pm Unchanged | 13G | VINCERX PHARMA, INC VINC | SAGE RHINO CAPITAL LLC | 0 0% | 0 (Unchanged) | View |
| 2021-02-16 4:30 pm Purchase | 13G | VINCERX PHARMA, INC VINC | CITADEL ADVISORS LLC | 637,931 4.5% | 637,931 (New Position) | View |